Sonic can't rely on US for growth: Smith
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Citigroup analyst Alex Smith says Sonic Healthcare can’t rely on the US for top and bottom line growth.
“The second quarter earnings of Quest and Labcorp show organic volume growth remains weak in the US pathology market, prices are declining,” says Smith. “This is expected to continue for the foreseeable future (and) Sonic needs significant cost reductions to offset these headwinds.”
Sonic Healthcare is trading at about 15 times earnings. That’s too expensive, says Smith. He is “cautious” on the stock and doesn’t recommend investors buy it or sell it.
At 1320 AEST Sonic Healthcare shares were up 16 cents, or 1.1%, to $14.60, after earlier rising as high as $14.65. The stock has gained 16% in the last 12 months and is up 9.5% this year. The S&P/ASX200 Index is up 22% in the last 12 months and 7.9% this year.